XML 33 R20.htm IDEA: XBRL DOCUMENT v3.5.0.2
Stock-Based Compensation
12 Months Ended
Jun. 30, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]  
Stock-Based Compensation
Stock-Based Compensation
Our shareholders previously approved the adoption of and subsequent amendments to the Lancaster Colony Corporation 2005 Stock Plan (the “2005 Plan”). The 2005 Plan reserved 2,000,000 common shares for issuance to our employees and directors. As the 2005 Plan expired in May 2015, we obtained shareholder approval of the Lancaster Colony Corporation 2015 Omnibus Incentive Plan (the “2015 Plan”) at our November 2015 Annual Meeting of Shareholders. The 2015 Plan did not affect any currently outstanding equity awards granted under the 2005 Plan. The 2015 Plan reserved 1,500,000 common shares for issuance to our employees and directors. All awards granted under these plans will be exercisable at prices not less than fair market value as of the date of the grant. The vesting period for awards granted under these plans varies as to the type of award granted, but generally these awards have a maximum term of five years.
We recognize compensation expense over the requisite service period of the grant. Compensation expense is reflected in Cost of Sales or Selling, General and Administrative Expenses based on the grantees’ salaries expense classification. We record tax benefits and excess tax benefits related to stock-settled stock appreciation rights (“SSSARs”) and restricted stock awards. These excess tax benefits are included in the financing section of the Consolidated Statements of Cash Flows. As needed, we estimate a forfeiture rate for our SSSARs and restricted stock grants based on historical experience.
Stock-Settled Stock Appreciation Rights
We use periodic grants of SSSARs as a vehicle for rewarding certain employees with long-term incentives for their efforts in helping to create long-term shareholder value. We calculate the fair value of SSSARs grants using the Black-Scholes option-pricing model. Our policy is to issue shares upon SSSARs exercise from new shares that had been previously authorized.
In 2016, 2015 and 2014, we granted SSSARs to various employees under the terms of the plans. The following table summarizes information relating to these grants:
 
2016
 
2015
 
2014
SSSARs granted
240

 
149

 
146

Weighted average grant date fair value per right
$
12.23

 
$
9.94

 
$
11.84

Weighted average assumptions used in fair value calculations:
 
 
 
 
 
Risk-free interest rate
0.86
%
 
0.86
%
 
0.75
%
Dividend yield
1.93
%
 
2.02
%
 
1.97
%
Volatility factor of the expected market price of our common stock
20.88
%
 
19.62
%
 
22.35
%
Weighted average expected life in years
2.69

 
2.71

 
3.12


For these grants, the volatility factor was estimated based on actual historical volatility of our stock for a time period equal to the term of the SSSARs. The expected average life was determined based on historical exercise experience for this type of grant. The SSSARs we grant vest one-third on the first anniversary of the grant date, one-third on the second anniversary of the grant date and one-third on the third anniversary of the grant date.
The following table summarizes our continuing operations SSSARs compensation expense and tax benefits recorded for each of the years ended June 30:
 
2016
 
2015
 
2014
Compensation expense
$
1,472

 
$
1,288

 
$
1,092

Tax benefits
$
515

 
$
451

 
$
382

Intrinsic value of exercises
$
3,788

 
$
1,162

 
$
2,692

Excess tax benefits
$
1,341

 
$
410

 
$
942


The total fair values of SSSARs vested for each of the years ended June 30 were as follows:
 
2016
 
2015
 
2014
Fair value of vested rights
$
1,192

 
$
1,252

 
$
1,145


 The following table summarizes the activity relating to SSSARs granted under the plans for the year ended June 30, 2016:
 
Number of
Rights
 
Weighted
Average
Exercise
Price
 
Weighted
Average
Remaining
Contractual
Life in
Years
 
Aggregate
Intrinsic
Value
Outstanding at beginning of year
395

 
$
84.24

 
 
 
 
Exercised
(180
)
 
$
79.11

 
 
 
 
Granted
240

 
$
103.87

 
 
 
 
Forfeited
(20
)
 
$
88.72

 
 
 
 
Outstanding at end of year
435

 
$
97.01

 
3.97
 
$
13,302

Exercisable and vested at end of year
62

 
$
84.26

 
2.52
 
$
2,673

Vested and expected to vest at end of year
408

 
$
96.74

 
3.93
 
$
12,594


The following table summarizes information about the SSSARs outstanding by grant year at June 30, 2016:
 
 
Outstanding
 
Exercisable
 
 
 
 
 
 
Weighted Average
 
 
 
 
Grant Years
 
Range of
Exercise Prices
 
Number
Outstanding
 
Remaining
Contractual
Life in
Years
 
Exercise
Price
 
Number
Exercisable
 
Weighted
Average
Exercise
Price
2016
 
$101.70-$112.62
 
240
 
4.68
 
$103.87
 
 
$—
2015
 
$91.13
 
113
 
3.65
 
$91.13
 
20
 
$91.13
2014
 
$79.78-$89.29
 
64
 
2.65
 
$89.11
 
24
 
$89.07
2013
 
$72.67
 
7
 
1.66
 
$72.67
 
7
 
$72.67
2012
 
$63.50-$68.12
 
11
 
0.65
 
$68.12
 
11
 
$68.12

At June 30, 2016, there was $3.1 million of unrecognized compensation expense related to SSSARs that we will recognize over a weighted-average period of 2 years.
Restricted Stock
We use periodic grants of restricted stock as a vehicle for rewarding our nonemployee directors and certain employees with long-term incentives for their efforts in helping to create long-term shareholder value.
In 2016, 2015 and 2014, we granted shares of restricted stock to various employees under the terms of the plans. The following table summarizes information relating to these grants:
 
2016
 
2015
 
2014
Employees
 
 
 
 
 
Restricted stock granted
28

 
9

 
24

Grant date fair value
$
2,923

 
$
845

 
$
2,190

Weighted average grant date fair value per award
$
102.89

 
$
91.13

 
$
89.21


The restricted stock under these employee grants vests on the third anniversary of the grant date. Under the terms of our grants, employees receive dividends on unforfeited restricted stock regardless of their vesting status. In 2016, 2015 and 2014, 6,000, 20,000 and 6,000 shares, respectively, of employee restricted stock vested.
In 2016, 2015 and 2014, we also granted shares of restricted stock to our nonemployee directors under the terms of the plans. The following table summarizes information relating to each of these grants:
 
2016
 
2015
 
2014
Nonemployee directors
 
 
 
 
 
Restricted stock granted
6

 
7

 
6

Grant date fair value
$
639

 
$
639

 
$
490

Weighted average grant date fair value per award
$
112.05

 
$
92.92

 
$
84.42


The 2016 grant vests over a one-year period, and all of these shares are expected to vest. Dividends earned on the stock during the vesting period will be paid to the directors at the time the stock vests. In 2016, 2015 and 2014, 7,000, 6,000 and 7,000 shares, respectively, of nonemployee director restricted stock vested, and the directors were paid the related dividends.
The following table summarizes our continuing operations restricted stock compensation expense and tax benefits recorded for each of the years ended June 30:
 
2016
 
2015
 
2014
Compensation expense
$
1,854

 
$
1,752

 
$
1,434

Tax benefits
$
649

 
$
613

 
$
502

Excess tax benefits
$
76

 
$
153

 
$
78


The total fair values of restricted stock vested for each of the years ended June 30 were as follows:
 
2016
 
2015
 
2014
Fair value of vested shares
$
1,124

 
$
1,836

 
$
931


The following table summarizes the activity relating to restricted stock granted under the plans for the year ended June 30, 2016:
 
Number of
Shares
 
Weighted
Average Grant
Date Fair Value
Unvested restricted stock at beginning of year
45

 
$
87.71

Granted
34

 
$
104.43

Vested
(13
)
 
$
83.59

Forfeited
(3
)
 
$
86.48

Unvested restricted stock at end of year
63

 
$
97.71


At June 30, 2016, there was $3.5 million of unrecognized compensation expense related to restricted stock that we will recognize over a weighted-average period of 2 years.